Image pharmaphorum Editor Oncology Beyond traditional cancer treatment: Can we confront unmet n... Surgery, chemotherapy, radiotherapy, and immunotherapy are designed to kill cancer, but what if we could control cancer? R&D The growth of radiotherapeutics: Addressing supply chain com... Players, current and emergent, should prepare for complexities in the supply chain as radiotherapeutics continues to rise. Sales & Marketing Sponsored Go slow to go fast: Setting a content transformation journey... Pharma marketing is evolving and it’s evolving quickly. How can organisations successfully ride the wave of this transformation? Digital Frontiers Health 2024: Day Two We are back for Day Two of Frontiers Health, coming to you live from the heart of Berlin! Load more results
Oncology Beyond traditional cancer treatment: Can we confront unmet n... Surgery, chemotherapy, radiotherapy, and immunotherapy are designed to kill cancer, but what if we could control cancer?
R&D The growth of radiotherapeutics: Addressing supply chain com... Players, current and emergent, should prepare for complexities in the supply chain as radiotherapeutics continues to rise.
Sales & Marketing Sponsored Go slow to go fast: Setting a content transformation journey... Pharma marketing is evolving and it’s evolving quickly. How can organisations successfully ride the wave of this transformation?
Digital Frontiers Health 2024: Day Two We are back for Day Two of Frontiers Health, coming to you live from the heart of Berlin!
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.